<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Once-in-a-lifetime screening for <z:hpo ids='HP_0100580'>Barrett esophagus</z:hpo> has been proposed for patients with <z:hpo ids='HP_0002020'>gastroesophageal reflux disease</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e>), but there is little evidence of its cost-effectiveness </plain></SENT>
<SENT sid="1" pm="."><plain>OBJECTIVE: 1) To determine the cost-effectiveness of screening high-risk groups for <z:hpo ids='HP_0100580'>Barrett esophagus</z:hpo> and providing surveillance to patients with <z:hpo ids='HP_0100580'>Barrett esophagus</z:hpo> and <z:mpath ids='MPATH_589'>dysplasia</z:mpath> or to <z:hpo ids='HP_0000001'>all</z:hpo> patients with <z:hpo ids='HP_0100580'>Barrett esophagus</z:hpo> and 2) to compare the results with the cost-effectiveness of no screening or surveillance </plain></SENT>
<SENT sid="2" pm="."><plain>DESIGN: A decision analytic model was developed to examine no screening or surveillance and screening and surveillance for <z:hpo ids='HP_0100580'>Barrett esophagus</z:hpo> with <z:mpath ids='MPATH_589'>dysplasia</z:mpath> only or <z:hpo ids='HP_0100580'>Barrett esophagus</z:hpo> without <z:mpath ids='MPATH_589'>dysplasia</z:mpath> every 2 to 5 years </plain></SENT>
<SENT sid="3" pm="."><plain>Low- or high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> received surveillance every 6 or 3 months, respectively </plain></SENT>
<SENT sid="4" pm="."><plain>DATA SOURCES: Published literature and the Health Care Financing Administration </plain></SENT>
<SENT sid="5" pm="."><plain>TARGET POPULATION: 50-year-old white men with symptoms of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>TIME HORIZON: 50 years of age until 80 years of age or <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>PERSPECTIVE: Third-party payer </plain></SENT>
<SENT sid="8" pm="."><plain>OUTCOME MEASURE: Incremental cost-effectiveness ratio </plain></SENT>
<SENT sid="9" pm="."><plain>RESULTS OF BASE-CASE ANALYSIS: Screening with surveillance limited to patients with <z:hpo ids='HP_0100580'>Barrett esophagus</z:hpo> with <z:mpath ids='MPATH_589'>dysplasia</z:mpath> required $10 440 per quality-adjusted life-year (QALY) saved compared to no screening or surveillance </plain></SENT>
<SENT sid="10" pm="."><plain>The incremental cost-effectiveness ratio of surveillance every 5 years in patients with <z:hpo ids='HP_0100580'>Barrett esophagus</z:hpo> without <z:mpath ids='MPATH_589'>dysplasia</z:mpath> compared to surveillance of patients with <z:hpo ids='HP_0100580'>Barrett esophagus</z:hpo> with <z:mpath ids='MPATH_589'>dysplasia</z:mpath> was $596 000 per QALY saved </plain></SENT>
<SENT sid="11" pm="."><plain>RESULTS OF SENSITIVITY ANALYSIS: The annual incidence of <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> must exceed 1 case per 54 patient-years of follow-up (1.9%) for surveillance of <z:hpo ids='HP_0100580'>Barrett esophagus</z:hpo> without <z:mpath ids='MPATH_589'>dysplasia</z:mpath> every 5 years to yield an incremental cost-effectiveness ratio less than $50 000 per QALY saved </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: Screening 50-year-old men with symptoms of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e> to detect <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> associated with <z:hpo ids='HP_0100580'>Barrett esophagus</z:hpo> is probably cost-effective </plain></SENT>
<SENT sid="13" pm="."><plain>However, subsequent surveillance of patients with <z:hpo ids='HP_0100580'>Barrett esophagus</z:hpo> but no <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, even at 5-year intervals, is an expensive practice </plain></SENT>
</text></document>